- cafead Feb 07, 2024 at 11:32: AM
via Gilead will not buy immunotherapy biotech Tizona Therapeutics, backing out of an option that the company paid $300 million for in 2020.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Gilead will not buy Tizona after paying $300M for the right to do so
- Thread starter cafead
- Start date
<
Similar threads